Literature DB >> 382647

Combined modality therapy of malignant melanoma.

E M Hersh, J U Gutterman, C M McBride.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 382647     DOI： 10.1007/bf01556586

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  77 in total

1.  Radiation therapy of malignant melanoma: experience with high individual treatment doses.

Authors:  H J Habermalz; J J Fischer
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

2.  Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study.

Authors:  T K Gupta
Journal:  Ann Surg       Date:  1977-08       Impact factor: 12.969

3.  Controlled trial of active immunotherapy in management of stage IIB malignant melanoma.

Authors:  M B McIllmurray; M J Embleton; W G Reeves; M J Langman; M Deane
Journal:  Br Med J       Date:  1977-02-26

4.  Immunotherapy of malignant melanoma. A clinical trial.

Authors:  W H Mccarthy; G Cotton; A Carlon; G W Milton; S Kossard
Journal:  Cancer       Date:  1973-07       Impact factor: 6.860

5.  BCG immunotherapy of a mucous membrane malignant melanoma. Report of a case.

Authors:  M E Pliskin; M J Mastrangelo; R Bellet; J Berkelhammer
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1976-07

6.  Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.

Authors:  G Beretta; G Bonadonna; N Cascinelli; A Morabito; U Veronesi
Journal:  Cancer Treat Rep       Date:  1976-01

7.  Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.

Authors:  M J Mastrangelo; R E Bellet; J Berkelhammer; W H Clark
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

8.  Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.

Authors:  W A Cassel; D R Murray; A H Torbin; Z L Olkowski; M E Moore
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

9.  A Phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma.

Authors:  J F Laucius; A J Bodurtha; J M Mastrangelo; R E Bellet
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

10.  Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.

Authors:  G A Currie; T J McElwain
Journal:  Br J Cancer       Date:  1975-02       Impact factor: 7.640
View more
  1 in total

1.  Adjuvant BCG immunotherapy for malignant melanoma.

Authors:  A H Paterson; D J Willans; L M Jerry; J Hanson; T A McPherson
Journal:  Can Med Assoc J       Date:  1984-10-01       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.